Background New agents with neuroprotective or neuroregenerative potential might be explored in primary-progressive Multiple Sclerosis (PPMS) - the MS disease course with leading neurodegenerative pathology. Identification of patients with a high short-term risk for progression may minimize study duration and sample size. Cohort studies reported several variables as predictors of EDSS disability progression but findings were partially contradictory. Objective To analyse the impact of published predictors on EDSS disease progression in a large cohort of PPMS patients. Methods A systematic literature research was performed to identify predictors for disease progression in PPMS. Individual case data from the Sylvia Lawry Centre (SLC) and the Hamburg MS patient database (HAPIMS) was pooled for a retrospective validation of these predictors on the annualized EDSS change. Results The systematic literature analysis revealed heterogeneous data from 3 prospective and 5 retrospective natural history cohort studies. Age at onset, gender, type of first symptoms and early EDSS changes were available for validation. Our pooled cohort of 597 PPMS patients (54% female) had a mean follow-up of 4.4 years and mean change of EDSS of 0.35 per year based on 2503 EDSS assessments. There was no significant association between the investigated variables and the EDSS-change. Conclusion None of the analysed variables were predictive for the disease progression measured by the annualized EDSS change. Whether PPMS is still unpredictable or our results may be due to limitations of cohort assessments or selection of predictors cannot be answered. Large systematic prospective studies with new endpoints are needed.
References
[1]
Koch M, Kingwell E, Rieckmann P, Tremlett H (2009) The natural history of primary progressive multiple sclerosis. Neurology 73: 1996–2002 doi:10.1212/WNL.0b013e3181c5b47f.
[2]
Fox RJ, Thompson A, Baker D, Baneke P, Brown D, et al.. (2012) Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS. Mult Scler. doi:10.1177/1352458512458169.
[3]
Antel J, Antel S, Caramanos Z, Arnold DL, Kuhlmann T (2012) Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol: 627–638. doi:10.1007/s00401-012-0953-0.
[4]
Sola P, Mandrioli J, Simone AM, Ferraro D, Bedin R, et al. (2011) Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM. Mult Scler 17: 303–311 doi:10.1177/1352458510386996.
[5]
Tremlett H, Paty D, Devonshire V (2005) The natural history of primary progressive MS in British Columbia, Canada. Neurology 65: 1919–1923 doi:10.1212/01.wnl.0000188880.17038.1d.
[6]
Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, et al. (2009) A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler 15: 1195–1205 doi:10.1177/1352458509106937.
[7]
Rice GPA, Filippi M, Comi G, Clinical C, Group S (2011) Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Most.
[8]
Wolinsky JS, Narayana PA, O’Connor P, Coyle PK, Ford C, et al. (2007) Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61: 14–24 doi:10.1002/ana.21079.
[9]
P？hlau D, Przuntek H, Sailer M, Bethke F, Koehler J, et al. (2007) Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler 13: 1107–1117 doi:10.1177/1352458507078400.
[10]
Miller DH, Leary SM, Thompson AJ (2004) Overview of London trial of intramuscular interferon-β 1a in primary-progressive multiple sclerosis. Mult Scler 10: 56–57 doi:10.1191/1352458504ms1031oa.
[11]
Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, et al. (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66: 460–471 doi:10.1002/ana.21867.
[12]
Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH (2008) Disability as an outcome in MS clinical trials. Neurology 71: 624–631 doi:10.1212/01.wnl.0000313034.46883.16.
[13]
European Medicines Agency (2012) Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis.
[14]
Vukusic S, Confavreux C (2003) Primary and secondary progressive multiple sclerosis. J Neurol Sci 206: 153–155. doi: 10.1016/s0022-510x(02)00427-6
[15]
Kremenchutzky M, Rice GPA, Baskerville J, Wingerchuk DM, Ebers GC (2006) The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 129: 584–594 doi:10.1093/brain/awh721.
[16]
Khaleeli Z, Ciccarelli O, Manfredonia F, Barkhof F, Brochet B, et al. (2008) Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. Ann Neurol 63: 790–793 doi:10.1002/ana.21375.
[17]
Bosma LV, Kragt JJ, Knol DL, Polman CH, Uitdehaag BM (2012) Clinical scales in progressive MS: predicting long-term disability. Mult Scler 18: 345–350 doi:10.1177/1352458511419880.
[18]
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097 doi:10.1371/journal.pmed.1000097.
[19]
R Development Core Team (2010) R: A language and environment for statistical computing.
[20]
Andersson P, Waubant E (1999) Multiple Sclerosis That Is Progressive From the Time of Onset: Clinical Characteristics and Progression of Disability. Arch … 56: 1138–1142. doi: 10.1001/archneur.56.9.1138
[21]
Cottrell D a, Kremenchutzky M, Rice GP, Koopman WJ, Hader W, et al. (1999) The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 122 (Pt 4: 625–639. doi: 10.1093/brain/122.4.625
[22]
Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343: 1430–1438. doi: 10.1056/nejm200011163432001
[23]
Confavreux C (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126: 770–782 doi:10.1093/brain/awg081.
[24]
Rovaris M, Judica E, Gallo A, Benedetti B, Sormani MP, et al. (2006) Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain 129: 2628–2634 doi:10.1093/brain/awl222.
[25]
Khaleeli Z, Ciccarelli O, Mizskiel K, Altmann D, Miller DH, et al. (2010) Lesion enhancement diminishes with time in primary progressive multiple sclerosis. Mult Scler 16: 317–324 doi:10.1177/1352458509358090.
[26]
Calabrese M, Poretto V, Favaretto A, Alessio S, Bernardi V, et al. (2012) Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 135: 2952–2961 doi:10.1093/brain/aws246.
[27]
Cottrell D a, Kremenchutzky M, Rice GP, Hader W, Baskerville J, et al. (1999) The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. Brain 122 (Pt 4: 641–647. doi: 10.1093/brain/122.4.641
[28]
Neuhaus A, Daumer M, O’Connor P (2006) Comparing several simple models to predict the development of disability in individual multiple sclerosis patients from their disability history. J Neurol 253: 58.
[29]
Weinshenker B, Issa M, Baskerville J (1996) Meta-analysis of the placebo-treated groups in clinical trials of progressive MS. Neurology: 1613–1619.
[30]
EMA (2013) European Medicines Agency - News and Events - Workshop on the clinical investigation of new medicines for the treatment of multiple sclerosis. Available: http://www.ema.europa.eu/ema/index.jsp?c？url=pages/news_and_events/events/2013/06？/event_detail_000724.jsp&mid=WC0b01ac058？004d5c3. Accessed 2013 Nov 21.
[31]
Ebers GC, Daumer M, Scalfari A, Rudick R, Kappos L, et al. (2011) Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach: Measuring disability in relapsing-remitting MS. Neurology 76: 1025–1026 doi:10.1212/WNL.0b013e31820a9674.
[32]
Rodrigues D-N, Paes RA, Vasconcelos CCF, Landeira-Fernandez J, Alvarenga MP (2011) Different cognitive profiles of Brazilian patients with relapsing-remitting and primary progressive multiple sclerosis. Arq Neuropsiquiatr 69: 590–595. doi: 10.1590/s0004-282x2011000500004
[33]
Denney DR, Lynch SG, Parmenter B a (2008) A 3-year longitudinal study of cognitive impairment in patients with primary progressive multiple sclerosis: speed matters. J Neurol Sci 267: 129–136 doi:10.1016/j.jns.2007.10.007.
[34]
Ebers GC (2004) Natural history of primary progressive multiple sclerosis. Mult Scler 10: 8–15 doi:10.1191/1352458504ms1025oa.
[35]
Bosma L, Kragt J, Polman C, Uitdehaag B (2012) Walking speed, rather than Expanded Disability Status Scale, relates to long-term patient-reported impact in progressive MS. Mult Scler. doi:10.1177/1352458512454346.
[36]
Zhang J, Waubant E, Cutter G, Wolinsky JS, Glanzman R (2011) Agreement of Expanded Disability Status Scale and timed 25-feet walk test in primary progressive multiple sclerosis: application in creating composite disability outcome endpoints. ECTRIMS.
[37]
Heesen C, B？hm J, Reich C, Kasper J, Goebel M, et al. (2008) Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler 14: 988–991 doi:10.1177/1352458508088916.
